An implanted brain-computer interface does not need to make its user smarter to become useful outside medicine. It only needs to make a common action faster, easier or possible without hands: moving a cursor, selecting an icon, writing a message, controlling augmented-reality glasses or issuing a command to another device.
That is a much more realistic route to human augmentation than the popular vision of instant knowledge uploads or chips that turn ordinary users into mathematical prodigies. Current invasive BCIs are still experimental medical systems, primarily designed for people with severe paralysis. But the capabilities being demonstrated in those trials already reveal which functions could eventually cross the boundary from therapy into elective enhancement.
The gap remains large. In Great Britain, Neuralink’s GB-PRIME study had seven implanted participants by January 2026. Its fully implanted N1 system records signals through more than 1,000 electrodes and is being tested to let people with severe neurological impairment control digital devices. This is not a consumer programme: the primary study lasts 12 months, requires repeated research sessions and is followed by three years of additional monitoring. Synchron is taking a different route with a 16-electrode endovascular interface delivered through the jugular vein rather than through open brain surgery. Its procedure takes roughly two hours in current studies, with most participants leaving hospital the following day.
These are impressive engineering achievements. They also expose the real barriers to everyday augmentation: surgery, long-term reliability, calibration, cybersecurity, data ownership, maintenance and regulation. A neural implant has to solve all of them before it can realistically compete with a phone, keyboard, smartwatch or pair of smart glasses.
The first augmentation will replace the mouse, not increase IQ
Today’s most mature implantable BCIs are essentially new input devices. They detect patterns of neural activity associated with an intended movement, attempted speech or another trained action and translate those patterns into commands.
That distinction matters. An implant does not simply open a general-purpose window into everything a person is thinking. Current systems typically require the user to perform or attempt specific tasks while software learns the relationship between recorded neural activity and the intended output. A decoder trained to move a cursor is not automatically capable of reconstructing childhood memories or discovering someone’s political opinions.
This is why the first practical augmentation market, if it develops, is likely to revolve around computer control.
A future elective implant could theoretically provide commands such as:
-
move and click a pointer without touching a mouse;
-
type or dictate text through attempted movement or speech;
-
select objects in an augmented-reality interface;
-
switch applications or execute shortcuts;
-
operate smart-home devices;
-
control robotics or machinery where conventional hand controls are inconvenient;
-
provide a private input channel when speaking aloud is undesirable.
Research already demonstrates enough bandwidth to make the idea credible. In one intracortical speech BCI study published in 2023, attempted speech was decoded at 62 words per minute using a vocabulary of 125,000 words, although the word error rate was still 23.8%. Another system using electrodes on the cortical surface reached a median 78 words per minute, with an error rate of about 25% on a substantially smaller vocabulary. A 2025 streaming speech neuroprosthesis reached about 47.5 words per minute with its broader vocabulary and more than 90 words per minute in a restricted 50-word task.
Those figures should not be mistaken for consumer specifications. They came from individual research participants using systems trained specifically for them. The equipment, training procedures and clinical support are nothing like the setup process for AirPods or an Apple Watch.
Still, they show where the practical value lies. Replacing ten taps, swipes and gestures with a reliable neural command could be commercially meaningful even if the implant never improves intelligence.
The strongest early consumer case would probably be hands-free computing combined with wearable displays. Smart glasses currently face an input problem: voice works poorly in quiet offices, public transport and private communication, while hand gestures are visible and sometimes awkward. A reliable neural input channel could solve that problem.
There is a catch. The alternatives are improving at the same time. Eye tracking, electromyography, voice recognition and camera-based gesture detection require no neurosurgery. An implant therefore cannot merely be slightly faster. Its advantage has to be large enough to justify having hardware permanently placed in or near the brain.
The same rule kills many futuristic augmentation concepts. A brain implant that saves 200 milliseconds when opening Spotify has no rational consumer proposition if a ring, watch or eye tracker delivers almost the same result without surgical risk.
Memory enhancement is considerably further away. Reading motor intention is one technical problem; writing useful information into distributed memory systems in the brain is another. Deep-brain stimulation already demonstrates that electrical stimulation can alter neural activity therapeutically, but that does not provide a general mechanism for installing memories, increasing IQ or uploading a language. Anyone selling those capabilities today is selling a claim, not a demonstrated consumer technology.
The real bottleneck is making an implant tolerable for years
Laboratory performance gets the headlines. Long-term ownership determines whether neural augmentation can become a product.
An implant intended for healthy people faces a harsher standard than one offered to somebody with profound paralysis. A person who has lost hand control may reasonably accept surgery, intensive training and uncertain device longevity in exchange for meaningful independence. A healthy software engineer considering an implant to type 15% faster will make a very different calculation.
Several engineering problems therefore become decisive.
First, signal stability. Penetrating electrodes provide highly detailed recordings because they sit close to neurons, but biological tissue does not behave like a USB port. The position and quality of recorded signals can change. Tissue responses, microscopic movement, electrode degradation and changing neural activity can alter decoder performance. Software can compensate for some drift, but frequent recalibration turns a supposed augmentation into maintenance work.
The endovascular approach used by Synchron reduces one surgical obstacle because electrodes are delivered through a blood vessel rather than inserted directly through the cortex. Its 16-channel Stentrode has demonstrated neural recording over extended periods in small clinical studies. The trade-off is obvious: placing fewer electrodes farther from individual neurons generally provides less spatial detail than dense intracortical arrays.
There is no universally superior architecture yet. The choice is between signal resolution, invasiveness and long-term practicality.
Second, surgery and revision risk. Relevant complications depend on the implantation method and can include infection, bleeding, vascular complications, seizures, damage to surrounding tissue and hardware failure. A device that lasts five years but requires another neurosurgical procedure to replace it has a very different risk profile from a wearable replaced every two years.
For an elective implant, manufacturers would need convincing answers to basic ownership questions:
-
What is the expected service life of the electrodes, battery and enclosure?
-
Can the implant be safely removed?
-
What happens if one electrode group fails?
-
Does a software update require recalibration?
-
Can the system still operate if the manufacturer closes?
-
Which MRI examinations remain possible?
-
Who pays for explantation after the warranty expires?
-
Is neural control available when the internet connection is down?
-
How long will security updates be supplied?
These are not peripheral questions. They determine whether implantation is a reversible technology choice or a long-term dependency on one company.
The current clinical workflow also shows how far the industry remains from consumer convenience. In Neuralink’s British GB-PRIME protocol, the primary study runs for 12 months, includes at least nine in-person research visits and asks participants to complete structured research sessions at least three times each week, typically for around an hour. The long-term follow-up then continues for another three years.
A commercial product obviously would not use an identical research protocol, but the comparison is useful. Today’s implanted BCIs still rely heavily on training, technical support and observation.
Third, power and connectivity. A completely implanted system needs energy, wireless communication or both. Charging must be easy enough to become routine, while radio connections have to remain reliable through tissue. Heat generation also matters because electronics cannot simply dissipate energy inside the skull the way a laptop does through a fan and metal chassis.
Then comes security.
A conventional data breach may expose passwords. A compromised BCI could expose patterns derived directly from neural activity. If future systems also stimulate the brain rather than merely record it, the cybersecurity threat becomes more serious because software could influence a physical interface connected to nervous tissue.
A credible consumer BCI should therefore be designed around local processing by default, encrypted communications, signed firmware, secure boot, tightly controlled software permissions and a physical mechanism for disabling external communication. Applications should receive only the minimum decoded command they need. A music app does not need a stream of raw cortical recordings simply because the user wants to skip a track.
The most irritating practical weakness may ultimately be software rather than surgery. Consumer electronics companies routinely abandon platforms after a few years. That business model is unacceptable when the discontinued accessory is inside someone’s skull. Before elective implants become sensible, the sector needs enforceable rules covering software support, data export, explantation and continuity of essential functions after a manufacturer leaves the market.
And there is currently no meaningful consumer price in Poland or the EU to quote. Implantable BCIs such as Neuralink and Synchron systems remain investigational rather than normal retail products. Any website claiming that a medically unneeded, implanted high-bandwidth BCI can currently be purchased in Poland for a specific commercial price should therefore be treated with suspicion.
In Europe, neural augmentation will be a rights issue as much as a product
A Polish consumer implant would not enter an empty legal environment.
When a BCI has a medical purpose, European medical-device rules are already demanding. Under the EU Medical Device Regulation, implantable devices used in direct contact with the central nervous system, as well as active implantable devices, fall into Class III, the highest-risk medical-device category. That means clinical evidence, conformity assessment and ongoing safety obligations matter far more than they do for ordinary electronics. In Poland, the relevant national medical-device authority is URPL.
Elective augmentation creates a more awkward problem.
The MDR does regulate some products without a medical purpose. Its Annex XVI includes, for example, certain equipment designed to stimulate the brain using electrical currents or magnetic or electromagnetic fields through the skull. Such non-medical brain-stimulation equipment has been placed in Class III.
But EU implementing rules explicitly distinguish those systems from invasive electrodes or sensors introduced partly or completely into the body. A future implanted, recording-only consumer BCI therefore cannot simply assume that the regulatory route for non-invasive brain stimulation automatically covers it. Intended purpose and product architecture will determine the legal pathway, and a manufacturer planning an augmentation implant would need to resolve classification before treating Europe as a conventional consumer-electronics market.
Data rules are equally important.
Raw neural recordings connected to an identifiable user are personal data. Where those signals reveal health information, or are processed as biometric information for identification, GDPR protections for special categories of personal data can also become relevant. The dangerous business model is easy to imagine: the implant is subsidised, but the company keeps extensive neural telemetry and uses derived information for advertising, profiling, insurance or workplace analytics.
A sensible user should reject that model.
For neural augmentation, consent cannot realistically mean clicking an 80-page privacy policy during setup. Users need separate controls for:
-
raw neural recordings;
-
decoded commands;
-
diagnostic telemetry;
-
model-training data;
-
cloud backups;
-
sharing with third-party applications;
-
research use;
-
deletion and account closure.
The distinction between raw signals and inferred information is particularly important. An electrical trace may look meaningless on its own, while a machine-learning model can convert patterns in that trace into information about attempted movement, speech or another state. Regulation and product design need to protect the inference, not merely the original waveform.
The EU AI Act adds another layer whenever artificial intelligence is used to interpret neural signals. Its general framework is already in force, with transparency obligations applying since 2 August 2026. Rules for certain high-risk AI systems in areas such as employment are scheduled to apply from 2 December 2027, while high-risk AI integrated into regulated products has a later application date of 2 August 2028.
For workplace augmentation, one limit is already particularly relevant: the AI Act prohibits AI-based emotion recognition in workplaces and educational institutions, except for specified medical or safety purposes. A company therefore cannot treat a neural interface as a convenient route around restrictions on algorithmically inferring employees’ emotions.
This matters because employment is one of the places where supposedly voluntary augmentation can become coercive very quickly. If implanted employees can operate software faster, an employer may be tempted to offer bonuses for adoption. The next step could be making implantation an informal requirement for promotion. At that point, the question is no longer whether the technology works. It is whether a worker can realistically refuse surgery without suffering a professional disadvantage.
That is also why UNESCO’s 2025 Recommendation on the Ethics of Neurotechnology focuses on mental privacy, autonomy and the sensitivity of neural information. The recommendation is not equivalent to an EU regulation, but it points toward the type of safeguards lawmakers are likely to expect as neurotechnology expands into employment, education and consumer markets.
For the European market, a technically impressive implant with weak privacy controls is therefore not close to being consumer-ready. The product has to work at four levels simultaneously: neurosurgery, electronics, AI software and fundamental-rights compliance.
FAQ: implanted BCIs in everyday use
Can a current brain implant read everything a person is thinking?
No. Present systems decode specific neural patterns under defined conditions after training. A BCI trained for intended hand movement or attempted speech does not provide unrestricted access to memories, beliefs or every internal thought.
Can a healthy person buy a Neuralink implant in Poland today?
No. Neuralink’s implanted BCI remains an investigational system used in authorised clinical research. It is not a normal consumer product sold in Poland or elsewhere in the EU for elective cognitive enhancement.
Would implantation automatically make someone more intelligent?
No demonstrated implant currently provides a general increase in intelligence. The realistic near-term capabilities are narrower: controlling devices, generating communication and potentially interacting with software more directly.
Which implanted BCI approach is least invasive?
Endovascular systems avoid open brain surgery by delivering electrodes through blood vessels, while intracortical systems place electrodes closer to neurons and can capture higher-resolution signals. Lower invasiveness and higher signal resolution currently involve trade-offs rather than one clearly superior solution.
How much would a consumer neural implant cost?
There is no credible retail figure because high-bandwidth implanted BCIs are not commercially available as elective consumer products. Quoting a Polish retail price today would create false precision. A future price would have to include not only hardware but surgery, imaging, hospital care, calibration, follow-up, software support and potentially explantation or revision.
Could an employer require workers to use a brain implant?
A mandatory invasive implant would raise major employment, privacy, bodily-autonomy and data-protection issues in Europe. AI-based emotion recognition in workplaces is already prohibited under the EU AI Act except for limited medical or safety uses. Even supposedly voluntary programmes would require scrutiny if refusing the implant carried professional consequences.
Could neural data be sold to advertisers?
A company processing identifiable neural information is subject to European data-protection requirements, and information revealing health or qualifying biometric characteristics receives additional protection. The practical rule for consumers should be stricter: a neural implant whose business model depends on selling behavioural or neural profiles should be rejected.
What is the biggest obstacle to consumer adoption?
Not electrode count. The bigger challenge is demonstrating that an implant can remain safe, secure, useful and supported for many years without repeated surgery or constant expert intervention. A spectacular laboratory demonstration does not solve the product-lifecycle problem.
The first decision for anyone evaluating neural augmentation should therefore be simple: ignore claimed performance until the manufacturer can document the full implant lifecycle. Check long-term safety data, expected hardware life, explantation procedure, offline functionality, cybersecurity support and ownership of raw neural data before looking at typing speed or electrode count. If those six questions do not have precise contractual and technical answers, the device is not ready for elective implantation—regardless of how impressive its demonstration looks.
